Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.
Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from diverse populations.
Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs ...
Collaboration aims to identify and validate novel targets with strong genetic evidence and clear therapeutic hypotheses The partnership between Novo Nordisk and Variant Bio is aimed at identifying ...
Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...
Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic disease targets.
(Cory Parris Photo) Variant Bio today announced a partnership with Novo Nordisk for disease research and development that could total $50 million for the biotech startup. The Seattle company is ...
2025 /PRNewswire/ -- Variant Bio, a genomics-driven drug discovery company, today announced a multi-year research collaboration with Novo Nordisk to discover novel targets for the treatment of ...